Correction to: In vitro drug testing using patient-derived ovarian cancer organoids (Journal of Ovarian Research, (2024), 17, 1, (194), 10.1186/s13048-024-01520-2)

Correction: J Ovarian Res 17, 194 (2024) Following publication of the original article [1], the authors identified an error in Table 1 caption and content. Incorrect table. The characteristics of patients with ovarian cancer (V5) Adjuvant chemotherapy Survival status BRCA geme status Organoid culture Organoid expansion Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 12 cycles, then second debulking then paclitaxel and carboplatin × 6 cycles Alive Wild type Success No Paclitaxel and carboplatin × 9 cycles Alive Unexamined Failed - Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 3 cycles, then gemcitabine and carboplatin × 3 cycles Expired Unexamined Success Yes Not received due to acute stroke Expired Unexamined Success Yes Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles Alive Wild type Success Yes Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles Alive Wild type Failed - Paclitaxel and carboplatin × 6 cycles, then lipodox × 6 cycles Alive Mutation Success Yes Paclitaxel and cisplatin × 4 cycles, then lipodox and bevacizumab × 5 cycles, then gemcitabine and bevacizumab × 2 cycles, then topotecan × 8 cycles Expired Unexamined Failed - Paclitaxel, carboplatin and bevacizumab × 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine × 2 cycles Expired Wild type Success Yes Paclitaxel and carboplatin × 4 cycles Alive Unexamined Success Yes Gemcitabine and carboplatin × 1 cycle Expired Unexamined Success Yes Rejected Expired Unexamined Success Yes Not received Alive Unexamined Success Yes Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycle Expired Wild type Success Yes Paclitaxel and cisplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine and cisplatin × 2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin × 2 cycles Alive Not received Success Yes Paclitaxel and carboplatin × 6 cycles, then lipodox and carboplatin × 4 cycles Alive Unexamined Success No Not received Alive Unexamined Success Yes Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycles Expired Wild type Success Yes Paclitaxel and carboplatin × 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab × 1 cycle, then gemcitabine, carboplatin and bevacizumab × 8 cycles Alive Unexamined Success Yes Paclitaxel and cisplatin × 1 cycle, then gemcitabine and paclitaxel × 3 cycles Expired Unexamined Failed - Paclitaxel and cisplatin × 6 cycles Alive Unexamined Success Yes Correct table. The characteristics of patients with ovarian cancer Original ID Sample ID Cancer type Age FIGO stage Neoadjuvant chemotherapy Debulking status Adjuvant chemotherapy Survival status BRCA geme status Organoid culture Organoid expansion OvCa-19 HGSC-1 High grade serous 54 IIIC Not received Suboptimal Paclitaxel and carboplatin x 6 cycles, followed by lipodox x12 cycles, then second debulking then paclitaxel and carboplatin x6 cycles Alive Wild type Success No OvCa-21 EM-1 Endometrioid 40 IC1 Not received Optimal Paclitaxel and carboplatin x 9 cycles Alive Unexamined Failed - OvCa-26 MC-1 Mucinous 37 IVB Not received Optimal Paclitaxel and carboplatin x 6 cycles, followed by lipodox x 3 cycles, then gemcitabine and carboplatin x3 cycles Expired Unexamined Success Yes OvCa-28 MC-2 Mucinous 66 IIIA Not received Optimal Not received due to acute stroke Expired Unexamined Success Yes OvCa-29 HGSC-2 High grade serous 61 IVB Not received Suboptimal Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles Alive Wild type Success Yes OvCa-32 HGSC-3 High grade serous 62 IVB Not received Suboptimal Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles Alive Wild type Failed - OvCa-33 HGSC-4 High grade serous 41 IIIC Not received Suboptimal Paclitaxel and carboplatin x 6 cycles, then lipodox x 6 cycles Alive Mutation Success Yes OvCa-34 MC-3 Mucinous 43 IC1 Not received Optimal Paclitaxel and cisplatin x4 cycles, then lipodox and bevacizumab x 5 cycles, then gemcitabine and bevacizumab x 2 cycles, then topotecan x 8 cycles Expired Unexamined Failed - OvCa-37 CCSC-1 Carcinosarcoma 61 IIIC Not received Optimal Paclitaxel, carboplatin and bevacizumab x 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine x2 cycles Expired Wild type Success Yes OvCa-38 CCC-1 Clear cell 32 IC1 Not received Optimal Paclitaxel and carboplatin x 4 cycles Alive Unexamined Success Yes OvCa-40 CCC-2 Clear cell 49 IIIC Bevacizumab, paclitaxel and cisplatin x 3 cycle then paclitaxel and carboplatin x 2 cycle Suboptimal Gemcitabine and carboplatin x1 cycle Expired Unexamined Success Yes OvCa-41 CCC-3 Clear cell 50 IIIB Not received Optimal Rejected Expired Unexamined Success Yes OvCa-42 MC-4 Mucinous 47 IC1 Not received Optimal Not received Alive Unexamined Success Yes OvCa-43 HGSC-5 High grade serous 55 IIIC Paclitaxel and carboplatin x 4 cycle Optimal Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycle Expired Wild type Success Yes OvCa-44 EM-2 Endometrioid 58 IIB Not received Suboptimal Paclitaxel and cisplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine and cisplatin x2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin x2 cycles Alive Unexamined Success Yes OvCa-45 HGSC-6 High grade serous 70 IIIC Not received Optimal Paclitaxel and carboplatin x 6 cycles, then lipodox and carboplatin x4 cycles Alive Unexamined Success No OvCa-46 MC-5 Mucinous 44 IC1 Not received Optimal Not received Alive Unexamined Success Yes OvCa-49 HGSC-7 High grade serous 55 IIIC Paclitaxel and cisplatin x 4 cycle Optimal Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycles Expired Wild type Success Yes OvCa-50 CCC-4 Clear cell 45 IIIC Not received Optimal Paclitaxel and carboplatin x 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab x 1 cycle, then gemcitabine, carboplatin and bevacizumab x 8 cycles. Alive Unexamined Success Yes OvCa-51 CCSC-2 Carcinosarcoma 51 IIIA2 Not received Optimal Paclitaxel and cisplatin x 1 cycle, then gemcitabine and paclitaxel x 3 cycles Expired Unexamined Failed - OvCa-54 CCC-6 Clear cell 51 IIB Not received Optimal Paclitaxel and cisplatin x 6 cycles Alive Unexamined Success Yes The original article [1] has been corrected.